Skip to main content
Clinical Trials/NCT06208436
NCT06208436
Recruiting
Not Applicable

The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer Stratified by Pathologic Risk Factors

Tianjin Medical University Cancer Institute and Hospital1 site in 1 country250 target enrollmentOctober 7, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pancreas Cancer
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Enrollment
250
Locations
1
Primary Endpoint
Recurrence-free survival
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

This study aimed to evaluate the impact of adjuvant chemotherapy on survival in patients with Stage I pancreatic cancer stratified by pathologic risk factors.

Registry
clinicaltrials.gov
Start Date
October 7, 2023
End Date
February 28, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jihui Hao

Professor

Tianjin Medical University Cancer Institute and Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients who underwent surgical resection and were pathologically diagnosed as PDAC between 2010 and

Exclusion Criteria

  • Patients with pN1-N2, patients with pT3-T4, patients with distant metastasis, patients who received neoadjuvant therapy, patients with R1 resection, and patients who died due to perioperative mortality within 30 days.

Outcomes

Primary Outcomes

Recurrence-free survival

Time Frame: January 2010 to February 2023

The period between surgical resection to the date of recurrence.

Secondary Outcomes

  • Overall survival(January 2010 to February 2023)

Study Sites (1)

Loading locations...

Similar Trials